Media stories about Second Sight Medical Products (NASDAQ:EYES) have been trending somewhat negative this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Second Sight Medical Products earned a news impact score of -0.03 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 47.1467057055212 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
EYES has been the subject of several analyst reports. ValuEngine upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Thursday, May 17th. Finally, HC Wainwright set a $5.00 price target on shares of Second Sight Medical Products and gave the company a “buy” rating in a research report on Tuesday, May 15th.
Second Sight Medical Products traded up $0.03, hitting $2.22, during trading on Thursday, according to MarketBeat Ratings. 300 shares of the company’s stock traded hands, compared to its average volume of 500,718. Second Sight Medical Products has a 12-month low of $0.90 and a 12-month high of $2.58. The firm has a market cap of $145.26 million, a price-to-earnings ratio of -3.71 and a beta of 3.05.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Thursday, May 10th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter. Second Sight Medical Products had a negative net margin of 387.35% and a negative return on equity of 307.76%. The business had revenue of $0.98 million for the quarter. equities analysts expect that Second Sight Medical Products will post -0.56 earnings per share for the current year.
In other news, Director Gregg Williams acquired 6,756,757 shares of the stock in a transaction dated Thursday, May 3rd. The stock was purchased at an average cost of $1.48 per share, with a total value of $10,000,000.36. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 34.70% of the company’s stock.
About Second Sight Medical Products
Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.